undamentalytics Newsletter
Sign in

Regenxbio Inc. balance sheet

At the end of fiscal 2025, Regenxbio Inc. had total assets of $453m, total liabilities of $350m and shareholders' equity of $103m. It held $34.5m in cash against $0 of debt: net cash of $34.5m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents1154254776703383459735583436
Receivables—12———38433228252026107
Total current assets—311893168338345531519416335278281236
Total assets—32211731995444987081,114833574466453387
Accounts payable—01254611112723232116
Deferred revenue (current)—————1—032001010
Total current liabilities—94101422348113013013010311883
Total debt00000000000000
Total liabilities—9511163548330350317262206350315
Shareholders' equity−14−1821716218350945037876451631226010372
Non-controlling interests and other (assets − liabilities − equity)—13————————————
Net debt (negative = net cash)−1−1−54−25−47−76−70−338−345−97−35−58−34−36
Shares outstanding—8m26m26m31m36m37m37m43m43m44m50m51m54m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NUVB vs RGNXABUS vs RGNXIBRX vs RGNX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regenxbio Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regenxbio Inc.